Indication
Intratumoral Injection
2 clinical trials
2 products
Clinical trial
Phase 1b/2a Study of RiMO-301 and Hypofractionated Radiotherapy With A PD-1 Inhibitor for the Treatment of Unresectable, Recurrent or Metastatic Head-Neck CancerStatus: Recruiting, Estimated PCD: 2026-06-01
Product
RiMO-301Clinical trial
Phase I Dose-Escalation Study of RiMO-401 With Radiation in Advanced TumorsStatus: Recruiting, Estimated PCD: 2026-01-01
Product
RiMO-401